Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from high-sodium oxybate to XYWAV in narcolepsy to evaluate blood pressure change
2023-504892-25-00Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of sodium oxybate + calcium oxybate + potassium oxybate + magnesium oxybate in narcolepsy, sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Change from baseline to end of treatment in 24-hour average systolic blood pressure. Started Nov 2023; status: completed.
02
Drugs
sodium oxybate + calcium oxybate + potassium oxybate + magnesium oxybate
03
Conditions
narcolepsy
Beyond the preview
Go deeper on 2023-504892-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504892-25-00.